A UK-based cohort study comparing over 25,000 patients treated with GLP-1 RAs to 67,000 patients on SGLT-2 inhibitors found that GLP-1 RA use was significantly associated with a higher risk of intestinal obstruction, observed around 1.6 years of treatment. The gene discussed is GCG; the disease is intestinal obstruction.